Matummab -: Solid tumor therapy humanized anti-EGFR monoclonal antibody

被引:0
作者
Sorbera, LA [1 ]
Bozzo, J [1 ]
Bayés, M [1 ]
机构
[1] Prous Sci, Barcelona 08080, Spain
关键词
D O I
10.1358/dof.2005.030.03.884922
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Membrane tyrosine kinase receptors in cancer cells are a particularly attractive therapeutic target. The epidermal growth factor (EGF) family of membrane receptors, and the epidermal growth factor receptor (EGFR) in particular, has emerged as one of the most promising targets. Ligand binding to the EGFR initiates multiple growth-regulatory signaling pathways, including the mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K)/Akt pathways which regulate cellular gene transcription/proliferation and prosurvival signaling, respectively. One possible strategy to pharmacologically target EGFR is the use of anti-EGFR monoclonal antibodies (MAbs) to compete with activating EGFR ligands for binding to the extracellular domain. Matuzumab (EMD-72000) is a humanized IgG(1) MAb that not only binds with high specificity and affinity to EGFR, but also modulates antibody-dependent cellular cytotoxicity (ADCC). It has shown excellent antitumor activity against several human tumor types, including head and neck, lung, gastric and pancreatic cancers, and was chosen for further development. The efficacy, safety and pharmacokinetics of matuzumab as a single agent or in combination with other chemotherapeutics have been reported in several clinical trials. Matuzumab is presently undergoing phase II development for the treatment of solid tumors, including cervical, gastric, ovarian and non-small cell lung cancer (NSCLC).
引用
收藏
页码:240 / 247
页数:8
相关论文
共 41 条
[21]  
LO KM, 2003, AACR NCI EORTC INT C
[22]   A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus [J].
Mayo, LD ;
Donner, DB .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (20) :11598-11603
[23]   The single transmembrane domains of ErbB receptors self-associate in cell membranes [J].
Mendrola, JM ;
Berger, MB ;
King, MC ;
Lemmon, MA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (07) :4704-4712
[24]  
Moscatello DK, 1996, ONCOGENE, V13, P85
[25]   The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification [J].
Prenzel, N ;
Fischer, OM ;
Streit, S ;
Hart, S ;
Ullrich, A .
ENDOCRINE-RELATED CANCER, 2001, 8 (01) :11-31
[26]   The target of rapamycin (TOR) proteins [J].
Raught, B ;
Gingras, AC ;
Sonenberg, N .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (13) :7037-7044
[27]   NF-κB is a target of AKT in anti-apoptotic PDGF signalling [J].
Romashkova, JA ;
Makarov, SS .
NATURE, 1999, 401 (6748) :86-90
[28]  
ROSEN O, 2003, P AM ASS CANC RS, V44
[29]   Cell Signaling by Receptor Tyrosine Kinases [J].
Lemmon, Mark A. ;
Schlessinger, Joseph .
CELL, 2010, 141 (07) :1117-1134
[30]  
Sulica A, 1995, NAT IMMUN, V14, P123